Evidence map›Paper›PMID 29702736›Full record

ArticleClinical and translational science2018

Sorafenib Dose Recommendation in Acute Myeloid Leukemia Based on Exposure-FLT3 Relationship.

Tao Liu, Vijay Ivaturi, Philip Sabato, Jogarao V S Gobburu, Jacqueline M Greer, John J Wright, B Douglas Smith, Keith W Pratz, Michelle A Rudek, ETCTN-6745 study team

Erratum issuedOpen access · goldAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational science, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Review
  6. Which FLT3 Inhibitor for Treatment of AML?Current treatment options in oncology · 2022
    Review
  7. Article
  8. A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2020
    Article
  9. Review
  10. FLT3 inhibitors in acute myeloid leukemia.Journal of hematology & oncology · 2018
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Tao LiuCenter for Translational Medicine, University of Maryland Baltimore, Maryland, USA.
Vijay IvaturiCenter for Translational Medicine, University of Maryland Baltimore, Maryland, USA.
Philip SabatoCenter for Translational Medicine, University of Maryland Baltimore, Maryland, USA.
Jogarao V S GobburuCenter for Translational Medicine, University of Maryland Baltimore, Maryland, USA.
Jacqueline M GreerThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA.
John J WrightInvestigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA.
B Douglas SmithThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA.
Keith W PratzThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA.
Michelle A RudekThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA.
ETCTN-6745 study teamCenter for Translational Medicine, University of Maryland Baltimore, Maryland, USA.
University of Maryland, Baltimore · USSidney Kimmel Comprehensive Cancer Center · USJohns Hopkins University · USNational Cancer Institute · US

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI WILLIAM George NELSON · 1985 to 2026
$208.6M
Institute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1M
The Johns Hopkins Translational Science Team for the ET-CTNUM1CA186691 · NCI · JOHNS HOPKINS UNIVERSITY · PI Jan Hendrik Beumer, Michael A Carducci · 2014 to 2026
$21.9M
PHASE I TRIALS OF ANTICANCER AGENTSU01CA070095 · NCI · JOHNS HOPKINS UNIVERSITY · PI CARDUCCI, MICHAEL A · 1995 to 2013
$8.6M
Wisconsin and New Jersey Alliance in Precision Experimental TherapeuticsUM1CA186716 · NCI · RBHS -CANCER INSTITUTE OF NEW JERSEY · PI JABBOUR, SALMA, LIU, GLENN · 2014 to 2019
$4.1M
NCATS NIH HHS UL1 TR001079NCI NIH HHS P30 CA006973NCI NIH HHS U01 CA070095NCI NIH HHS UM1 CA186691NCI NIH HHS UM1 CA186716
6 · The paper itself

Abstract

Sorafenib administered at the approved dose continuously is not tolerated long-term in patients with acute myeloid leukemia (AML). The purpose of this study was to optimize the dosing regimen by characterizing the sorafenib exposure-response relationship in patients with AML. A one-compartment model with a transit absorption compartment and enterohepatic recirculation described the exposure. The relationship between sorafenib exposure and target modulation of kinase targets (FMS-like tyrosine kinase 3 (FLT3)-ITD and extracellular signal-regulated kinase (ERK)) were described by an inhibitory maximum effect (E

Indexed as

AdultAgedAntineoplastic AgentsApoptosisDose-Response Relationship, DrugDrug Administration ScheduleFemalefms-Like Tyrosine Kinase 3HumansInhibitory Concentration 50Leukemia, Myeloid, AcuteMaleMiddle AgedModels, BiologicalSorafenibTreatment OutcomeAntineoplastic AgentsFLT3 protein, humanfms-Like Tyrosine Kinase 3Sorafenib

Identifiers

PMID29702736
PMCPMC6039208
OpenAlexW2800959139

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.